News
Media
Conferences
CME/CE
Partners
Publications
Resources
Subscribe

|Videos|October 3, 2022

SRNA Roundtable Discussion: Diagnosis, Presentation, and Treatment Decision Differences Among Rare Neuroimmune Disorders

Author(s)Brenda L. Banwell, MD, Sean Pittock, MD, Michael Levy, MD, PhD

Experts such as Brenda Banwell, MD; Sean Pittock, MD; and Michael Levy, MD, PhD, cover topics related to differences in rare neuroimmune disorders, how they're approached and treated.

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Related Content

NeurologyLive® Friday 5 — September 11, 2026

ByIsabella Ciccone, MPH

September 11th 2026

Brain Chat: Say it More, Say it Better: How to Talk With Your Healthcare Team

ByMitzi Joi Williams, MD

September 11th 2026

CGRP-Therapy Atogepant Meets Primary and Secondary End Points in Phase 3 LUNA Trial for Menstrual Migraine

ByIsabella Ciccone, MPH

September 10th 2026

AAN, AHS Issue Updated Guideline on Pharmacologic Migraine Prevention in Adults: FAQs

September 10th 2026

FDA Priority Review Puts Satralizumab on Track as First MOGAD Drug

September 10th 2026

Latest CME

2026 Carolina Neuromuscular Disease Summit

In-Person + Virtual Event

2026 Carolina Neuromuscular Disease Summit

September 19-20, 2026

Increasing Awareness of Therapeutic Options for Thymidine Kinase 2 Deficiency (TK2d)

In-Person Event

Increasing Awareness of Therapeutic Options for Thymidine Kinase 2 Deficiency (TK2d)

October 16, 2026

Primary Care Education in Nashville

In-Person + Virtual Event

Primary Care Education in Nashville

October 20-21, 2026

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Zarazuela Zolkipli-Cunningham, MBChB, MRCP; Mary Kay Koenig, MD; Perry Shieh, MD, PhD, FAAN, FANA

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Basil T. Darras, MD

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Karissa Gable, MD

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Anne M. Connolly, MD, FAAN; Amy Moore, PhD

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

James F. Howard Jr, MD, FAAN; Katherine Ruzhansky, MD, MS

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Vinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA, FASCO; Girish Dhall, MD

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

Millie Das, MD; Wade Iams, MD, MSCI; Ruham Nasany, MD

Collaborating Across the Continuum™: Integrating Novel Therapies Into Multidisciplinary Treatment Plans for Generalized Myasthenia Gravis

Collaborating Across the Continuum™: Integrating Novel Therapies Into Multidisciplinary Treatment Plans for Generalized Myasthenia Gravis

Abigail Schwaede, MD; Alexis Lizarraga, MD, MS

Community Collab: The Evolving Role of FcRN Inhibitors in the Management of Generalized Myasthenia Gravis (gMG)

Community Collab: The Evolving Role of FcRN Inhibitors in the Management of Generalized Myasthenia Gravis (gMG)

James F. Howard Jr, MD, FAAN; Tuan Vu, MD

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Charu Aggarwal, MD, MPH, FASCO; Erminia Massarelli, MD, PhD, MS; Ruham Nasany, MD

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

FDA Priority Review Puts Satralizumab on Track as First MOGAD Drug

Gene Therapy ETX101 Shows Sustained Seizure Reductions, Neurodevelopmental Gains in Updated POLARIS Data

NeuroVoices: Jacqueline Becker, PhD, on Brain Fog, Alzheimer Risk, and Treatment Advances in Long COVID

AAN, AHS Issue Updated Guideline on Pharmacologic Migraine Prevention in Adults: FAQs

Once-Daily Trientine Enters Phase 3 Trial for First-Line Treatment in Wilson Disease